指南与共识膀胱癌与上尿路尿路上皮癌

欧洲泌尿外科学会2020版肌层浸润性与转移性膀胱癌指南摘要

European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines.
指南 / 共识 · Eur Urol · 2020-04-29

本指南为欧洲泌尿外科学会(EAU)2020年更新的肌层浸润性与转移性膀胱癌(MMIBC)指南摘要,基于截至2019年底的文献并纳入国际共识会议结果,围绕组织学、分期、预后因素及治疗给出循证推荐。强调高危非肌层浸润性与肌层浸润性非转移性膀胱癌以根治性膀胱切除加淋巴结清扫为标准治疗,适格患者术前给予顺铂为基础的新辅助化疗;转移性患者一线仍以顺铂为基础化疗为首选,并分层推荐免疫治疗与二线帕博利珠单抗。

要点

  • 高危非肌层浸润性与肌层浸润性非转移性膀胱癌推荐根治性膀胱切除加淋巴结清扫。
  • 适格浸润性肿瘤患者术前给予顺铂为基础的新辅助化疗。
  • 转移性一线顺铂为基础化疗,不适格者按PD-L1状态选择免疫治疗或卡铂。

核心结论

  • 2020版EAU指南为MMIBC的诊断与治疗提供更新推荐,供纳入临床实践。
  • 根治性膀胱切除加淋巴结清扫仍是最高危非肌层浸润性和肌层浸润性非转移性膀胱癌的推荐治疗。
  • 适格浸润性肿瘤患者行根治性膀胱切除前给予顺铂为基础的新辅助化疗。
  • 转移性适格患者一线仍以顺铂为基础化疗为首选;二线推荐帕博利珠单抗。

研究设计与样本

  • 自2017年发布(基于2016版指南)起每年进行覆盖MMIBC指南全部领域的广泛范围综述。
  • 检索数据库包括Medline、EMBASE和Cochrane Libraries,形成年度指南更新。
  • 对证据水平和推荐等级进行分级,并纳入晚期膀胱癌多利益相关方共识项目结果。
  • 指南推荐基于截至2019年底的当前文献,侧重随机临床试验和荟萃分析的高水平数据。

主要发现

  • 变异组织学在浸润性膀胱癌中的报告日渐增多,与治疗和预后相关。
  • 分期最好采用(增强)计算机断层扫描。
  • 治疗决策仍主要基于临床因素。
  • 开放与机器人根治性膀胱切除结果相当,前提是在有经验的中心实施。
  • 化疗后手术可能延长缓解者的生存;所有治疗与随访阶段均应监测生活质量。

关键数值与推荐

  • 开放根治性膀胱切除的最低遴选手术量为每年10例。
  • 对无原位癌且经最大程度切除的精选患者,放化疗可作为保留膀胱的替代方案。
  • 未接受新辅助化疗者应考虑辅助化疗;围手术期免疫治疗可在临床试验背景下提供。
  • 顺铂不适格患者中,PD-L1阳性者推荐免疫治疗,PD-L1阴性者推荐卡铂。
  • 精选男女患者可从保留性功能的根治性膀胱切除获益,但不推荐作为标准治疗。

临床怎么用

  • 按分期优选增强CT评估,治疗决策结合临床因素与患者适格性分层。
  • 适格肌层浸润性非转移性患者行根治性膀胱切除前给予顺铂为基础新辅助化疗,未行新辅助者考虑辅助化疗。
  • 转移性患者按顺铂适格性与PD-L1状态分层选择一线化疗或免疫治疗,二线可用帕博利珠单抗。
  • 保留膀胱仅限无原位癌且最大程度切除后的精选患者,采用放化疗替代。
  • 根治性膀胱切除应在有经验中心开展,开放手术年手术量至少10例,并全程监测生活质量。

局限性

  • 2020版指南推荐基于截至2019年底的文献。
  • 部分领域预期难以开展前瞻性对照研究,相关推荐来自多利益相关方共识项目。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: This overview presents the updated European Association of Urology (EAU) guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). OBJECTIVE: To provide practical evidence-based recommendations and consensus statements on the clinical management of MMIBC with a focus on diagnosis and treatment. EVIDENCE ACQUISITION: A broad and comprehensive scoping exercise covering all areas of the MMIBC guideline has been performed annually since its 2017 publication (based on the 2016 guideline). Databases covered by the search included Medline, EMBASE, and the Cochrane Libraries, resulting in yearly guideline updates. A level of evidence and a grade of recommendation were assigned. Additionally, the results of a collaborative multistakeholder consensus project on advanced bladder cancer (BC) have been incorporated in the 2020 guidelines, addressing those areas where it is unlikely that prospective comparative studies will be conducted. EVIDENCE SYNTHESIS: Variant histologies are increasingly reported in invasive BC and are relevant for treatment and prognosis. Staging is preferably done with (enhanced) computerised tomography scanning. Treatment decisions are still largely based on clinical factors. Radical cystectomy (RC) with lymph node dissection remains the recommended treatment in highest-risk non-muscle-invasive and muscle-invasive nonmetastatic BC, preceded by cisplatin-based neoadjuvant chemotherapy (NAC) for invasive tumours in "fit" patients. Selected men and women benefit from sexuality sparing RC, although this is not recommended as standard therapy. Open and robotic RC show comparable outcomes, provided the procedure is performed in experienced centres. For open RC 10, the minimum selected case load is 10 procedures per year. If bladder preservation is considered, chemoradiation is an alternative in well-selected patients without carcinoma in situ and after maximal resection. Adjuvant chemotherapy should be considered if no NAC was given. Perioperative immunotherapy can be offered in clinical trial setting. For fit metastatic patients, cisplatin-based chemotherapy remains the first choice. In cisplatin-ineligible patients, immunotherapy in Programmed Death Ligand 1 (PD-L1)-positive patients or carboplatin in PD-L1-negative patients is recommended. For second-line treatment in metastatic disease, pembrolizumab is recommended. Postchemotherapy surgery may prolong survival in responders. Quality of life should be monitored in all phases of treatment and follow-up. The extended version of the guidelines is available at the EAU website: https://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/. CONCLUSIONS: This summary of the 2020 EAU MMIBC guideline provides updated information on the diagnosis and treatment of MMIBC for incorporation into clinical practice. PATIENT SUMMARY: The European Association of Urology Muscle-invasive and Metastatic Bladder Cancer (MMIBC) Panel has released an updated version of their guideline, which contains information on histology, staging, prognostic factors, and treatment of MMIBC. The recommendations are based on the current literature (until the end of 2019), with emphasis on high-level data from randomised clinical trials and meta-analyses and on the findings of an international consensus meeting. Surgical removal of the bladder and bladder preservation are discussed, as well as the use of chemotherapy and immunotherapy in localised and metastatic disease.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Witjes JA, Bruins HM, Cathomas R, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol. 2020. PMID: 32360052. doi:10.1016/j.eururo.2020.03.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。